TRCT
GLMD icon

Tower Research Capital (TRC)’s Galmed Pharmaceuticals GLMD Stock Holding History

Tower Research Capital (TRC)’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7
Closed -$188 – 5422
2024
Q4 		$188 Sell
7
-15
-68% -$406 ﹤0.01% 5391
2024
Q3 		$1.19K Buy
+22
New +$768 ﹤0.01% 5193
2023
Q3 		– Sell
-1
Closed -$152 – 6041
2023
Q2 		$152 Buy
+1
New +$432 ﹤0.01% 5771
2021
Q4 		– Sell
-1
Closed -$5K – 6291
2021
Q3 		$5K Hold
1
– – ﹤0.01% 4860
2021
Q2 		$4K Sell
1
-1
-50% -$4.35K ﹤0.01% 4809
2021
Q1 		$9K Sell
2
-4
-67% -$22.1K ﹤0.01% 4421
2020
Q4 		$26K Sell
6
-1
-14% -$5K ﹤0.01% 3688
2020
Q3 		$35K Buy
+7
New +$45.7K ﹤0.01% 3676
2020
Q2 		– Sell
-1
Closed -$5K – 4830
2020
Q1 		$5K Sell
1
-3
-75% -$22.8K ﹤0.01% 2293
2019
Q4 		$37K Buy
+4
New +$27.5K ﹤0.01% 1521
2019
Q3 		– Sell
-4
Closed -$38K – 4242
2019
Q2 		$38K Buy
+4
New +$41.3K ﹤0.01% 1765
2019
Q1 		– Hold
0
– – – 3053
2018
Q4 		– Hold
0
– – – 4013
2018
Q3 		– Hold
0
– – – 3114
2017
Q3 		– Hold
0
– -$1K – 3919
2017
Q2 		– Hold
0
– – – 2485
2016
Q4 		– Hold
0
– – – 4032
2016
Q3 		– Hold
0
– – – 3925
2016
Q2 		– Hold
0
– – – 4151
2015
Q4 		– Hold
0
– -$1K – 4677
2015
Q3 		– Hold
0
– – – 3616
2015
Q2 		– Hold
0
– -$6K – 4612
2015
Q1 		– Sell
-1
Closed -$12K – 3139
2014
Q4 		$8K Buy
+1
New +$8.69K ﹤0.01% 2335
2014
Q3 		– Sell
-1
Closed -$19K – 4567
2014
Q2 		$19K Hold
1
– – ﹤0.01% 1869
2014
Q1 		$15K Buy
+1
New +$18.7K ﹤0.01% 2169

Other funds holding GLMD

SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

Tower Research Capital (TRC)'s GLMD Position: Q1 2025 in Review

Tower Research Capital (TRC) sold out of Galmed Pharmaceuticals (GLMD) in Q1 2025, closing a stake of 7 shares — an estimated $188 sold.

Tower Research Capital (TRC) first reported a position in GLMD in Q1 2014 and held it in 14 quarters. The position peaked at $38K in Q2 2019. 10 funds tracked by Wall St. Rank hold GLMD as of Q1 2025.

  • Tower Research Capital (TRC) reported no remaining Galmed Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 7 Galmed Pharmaceuticals shares in Q1 2025, an estimated $188.
  • Tower Research Capital (TRC) first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 14 quarters.
  • Tower Research Capital (TRC)'s Galmed Pharmaceuticals position peaked at $38K in Q2 2019.
  • 10 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.